Cargando…
Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report
Imatinib, a tyrosine kinase inhibitor has revolutionized the therapy of Philadelphia chromosome positive chronic myeloid leukemia. Side effects of imatinib include grade 1-4 hepatotoxicity in a subset of patients. We report the case of a 46-year-old male with chronic myeloid leukemia, who developed...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Cases Network Ltd
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2740313/ https://www.ncbi.nlm.nih.gov/pubmed/19829996 http://dx.doi.org/10.1186/1757-1626-2-7526 |